Why Private Prescription Beats NHS Routes for Weight Management
Is Mounjaro or Wegovy Better for Private Prescription Patients?
When comparing Mounjaro versus Wegovy through private prescription, the answer depends on individual clinical factors rather than one being universally superior. Wegovy contains semaglutide, a GLP-1 receptor agonist, while Mounjaro uses tirzepatide, a dual GIP/GLP-1 receptor agonist. Both require clinical assessment and work alongside a reduced-calorie diet and increased physical activity. The private route eliminates NHS barriers—no GP referral, no specialist weight management service waiting lists, and no 6-month delays that often discourage patients from starting treatment.
Private prescription through EverydayMeds offers identical medications to NHS patients but with immediate access. Our GPhC-registered pharmacy #9012878 supplies genuine Novo Nordisk Wegovy and Eli Lilly Mounjaro, not generic alternatives. Your prescriber reviews individual medical history, current medications, and weight management goals to determine which prescription-only medicine suits you best. This personalised approach often reveals preferences based on injection frequency, side effect profiles, or storage convenience rather than blanket superiority claims.
Wegovy vs Mounjaro Pricing: Private Prescription Cost Comparison
Understanding the true cost helps determine if Mounjaro or Wegovy offers better value through private prescription. Wegovy pricing starts at £79.99 for the 0.25mg starter dose (using code FIRST40 for new customers), progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Our Intro Trio bundle (0.25mg, 0.5mg & 1mg) provides three months of step-up dosing for £299.99. Returning customers benefit from code DOSE25 at checkout. Both medications require dose escalation over 16 weeks, making total treatment cost predictable unlike unpredictable NHS availability.
Mounjaro pricing follows similar patterns but with different dose increments due to its dual-receptor mechanism requiring adjusted titration schedules. Bundle options like the Progress Duo (0.5mg & 1mg Wegovy) at £189.99 offer convenience for patients stable on specific doses. Private prescription eliminates hidden costs—no specialist consultation fees, no repeated GP appointments, and no travel costs for hospital weight management clinics that NHS routes often require.
Clinical Evidence: Which Performs Better, Mounjaro or Wegovy?
Comparing clinical trial results directly would be misleading since Mounjaro and Wegovy studies used different populations, endpoints, and methodologies. Wegovy's STEP trials demonstrated significant results—STEP 1 showed approximately 15% average weight loss at 68 weeks versus 2.4% placebo, while STEP 5 maintained 15.2% reduction at 2 years as reported by Wilding et al., NEJM, 2021. The SELECT cardiovascular outcomes trial revealed 20% reduction in major adverse cardiovascular events.
Mounjaro's SURMOUNT trials similarly showed substantial weight management benefits, though direct percentage comparisons would be inappropriate given different trial designs. Both medications work as prescription-only medicines requiring clinical oversight, and both demonstrate efficacy when used alongside lifestyle modifications. Your EverydayMeds prescriber considers these evidence bases alongside your individual circumstances rather than applying population-level statistics to personal outcomes.
Mechanism Comparison: How Wegovy and Mounjaro Work Differently
Understanding whether Mounjaro or Wegovy suits you better requires grasping their distinct mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics naturally occurring incretin hormones, reducing appetite and promoting satiety after smaller meals. This single-pathway approach targets brain appetite centres and slows gastric emptying, creating natural portion control. Mounjaro's tirzepatide activates both GIP and GLP-1 receptors simultaneously, potentially offering dual metabolic benefits through complementary pathways. Both mechanisms support the feeling of fullness that helps patients adhere to reduced-calorie diets more easily than willpower alone.
Private Prescription Process: From Assessment to Delivery
The private prescription process for both Mounjaro and Wegovy eliminates NHS frustrations through streamlined clinical pathways. Our 3-minute online assessment captures medical history, current medications, weight management goals, and contraindications—far more efficient than multiple GP appointments. Qualified prescribers review applications within 72 hours (or 24 hours for express service), assessing suitability for either medication based on clinical guidelines and individual factors. Once approved, both treatments ship via next-day cold-chain delivery with temperature monitoring to ensure medication integrity. This process typically takes 4-5 days total versus 6+ months through NHS specialist services. No GP referral letters, no weight management clinic appointments, and no postcode lottery affecting access to treatment.
Storage and Practical Considerations: Wegovy vs Mounjaro Convenience
Practical differences often influence whether Mounjaro or Wegovy proves more convenient for private prescription patients. Wegovy offers superior storage flexibility—while both require refrigeration at 2-8°C before first use, Wegovy remains stable for 6 weeks at room temperature below 30°C once removed from the fridge. Mounjaro's room temperature stability lasts only 21 days, making Wegovy more travel-friendly for business trips or holidays. Both use pre-filled injection pens, but Wegovy's FlexTouch design from Novo Nordisk offers different ergonomics than Mounjaro's pen system. Dose escalation schedules differ slightly—Wegovy follows a standardised 16-week titration to 2.4mg maintenance, while Mounjaro's dual-receptor mechanism requires adjusted stepping protocols that your prescriber will explain during consultation.
Why Private Prescription Patients Choose EverydayMeds for Weight Management
Private prescription patients comparing Mounjaro versus Wegovy often discover that access speed matters more than theoretical medication superiority. NHS weight management services require BMI documentation, failed diet attempts, specialist referrals, and 6-month waiting lists that delay treatment when motivation peaks. EverydayMeds eliminates these barriers while maintaining clinical safety through qualified prescriber oversight and GPhC registration #9012878. Our transparent pricing removes NHS postcode lottery effects—London patients pay the same as rural Scotland customers.
Both medications arrive via professional cold-chain logistics that hospital pharmacies use, ensuring the same quality as NHS supply chains. Private prescription allows treatment continuation without service disruptions—no clinic closures, no formulary changes, and no rationing that affects NHS weight management programs. This consistency proves crucial for long-term success since both Mounjaro and Wegovy require sustained use alongside lifestyle modifications for optimal outcomes.
Making Your Decision: Start Your Private Prescription Journey Today
Rather than determining whether Mounjaro or Wegovy is definitively "better," focus on which suits your circumstances through private prescription access. EverydayMeds offers both options with qualified prescriber guidance to personalise your choice based on medical history, lifestyle factors, and treatment preferences. New customers use code FIRST40 at checkout, while returning patients apply DOSE25 for continued savings. Our clinical team ensures appropriate monitoring and dose adjustments throughout your weight management journey. Begin your 3-minute assessment today at https://everydaymeds.co.uk/collections/wegovy to discover which prescription-only medicine aligns with your goals. Both treatments are available with next-day delivery once clinical approval is complete, ending the frustration of NHS waiting lists while providing the same quality medications through professional pharmaceutical oversight.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
